Spectrum Pharmaceuticals (NASDAQ: SPPI) is one of 198 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare Spectrum Pharmaceuticals to related businesses based on the strength of its profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.
Institutional and Insider Ownership
66.4% of Spectrum Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.8% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 13.3% of Spectrum Pharmaceuticals shares are owned by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a breakdown of current recommendations and price targets for Spectrum Pharmaceuticals and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Spectrum Pharmaceuticals Competitors||483||2284||6245||120||2.66|
Spectrum Pharmaceuticals currently has a consensus price target of $24.25, indicating a potential upside of 23.79%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.49%. Given Spectrum Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe Spectrum Pharmaceuticals is more favorable than its competitors.
Risk & Volatility
Spectrum Pharmaceuticals has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, Spectrum Pharmaceuticals’ competitors have a beta of 1.63, indicating that their average stock price is 63% more volatile than the S&P 500.
Valuation & Earnings
This table compares Spectrum Pharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Spectrum Pharmaceuticals||$132.03 million||-$44.85 million||-19.79|
|Spectrum Pharmaceuticals Competitors||$206.18 million||-$2.14 million||2.43|
Spectrum Pharmaceuticals’ competitors have higher revenue and earnings than Spectrum Pharmaceuticals. Spectrum Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Spectrum Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Spectrum Pharmaceuticals Competitors||-3,962.76%||-118.15%||-43.78%|
Spectrum Pharmaceuticals beats its competitors on 7 of the 12 factors compared.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has three drugs in mid-to-late stage development, which include ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for immediate intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer (NMIBC), and POZIOTINIB, a pan-human epidermal growth factor receptor (HER) inhibitor used in the treatment of patients with a range of solid tumors, including breast and lung cancer.
What are top analysts saying about Spectrum Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Spectrum Pharmaceuticals Inc. and related companies.